PÚBLICO: “Infarmed Approves First Psychedelic for Severe Depression for Use in a Hospital Setting
Infarmed has approved public funding for the first medication containing escetamine, a psychedelic, to be used in a hospital setting for adults with severe depression.”
The Infarmed has approved the use in hospitals of Spravato (esketamine) to treat adults with depression that is treatment-resistant, by scheduling a significant significant in the therapeutic therapeutic in Portugal, as reported in the article linked by Público.
The decision appliesto to patients who did not responded to at at three courses of antidepressant and who have contraindications or refusal for electroconvulsive therapy.
A escetamine, a drug administered via the nasal route, offers an innovative innovative for serious severe of depression, it is used under strict clinical supervision.
The Clinic of Change offers a treatment program using esketamine (Spravato), which you can learn more about here.
With this measure, Portugal strengthens its commitment to treatments based on scientific , offering new hope to patients with depression severe that is treatment-resistant.
Read the full story here.
